Home
Storia in 1 fonti
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Curis (NASDAQ:CRIS)
Curis gained attention after positive emavusertib data as analyst raised its price target to $43 and highlighted upcoming trial catalysts.
Raccontata da
benzinga.com
Timeline cronologica
- ·
Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates - Curis (NASDAQ:C
Curis shares positive updated clinical data for emavusertib and increases its year-end guidance for the TakeAim CLL study.
- ·
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Curis (NASDAQ:CRIS)
Curis gained attention after positive emavusertib data as analyst raised its price target to $43 and highlighted upcoming trial catalysts.